Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | TACR1 | P25103 | 2/20 | 0.37 |
| ▸ | GHSR | Q92847 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13859079 | 0.86 | PLG (0.42) | MEN1KMT2ACCR2KCNH2SLC6A2 | |
| SCHEMBL14983612 | 0.85 | POLB (0.47) | POLBCCR2KCNH2SLC6A2SLC6A4 | |
| SCHEMBL14983613 | 0.85 | POLB (0.47) | POLBCCR2KCNH2SLC6A2SLC6A4 | |
| SCHEMBL13858858 | 0.85 | POLB (0.47) | POLBCCR2KCNH2SLC6A2SLC6A4 | |
| SCHEMBL13858982 | 0.84 | SLC6A4 (0.47) | SLC6A2SLC6A4HRH3TACR1ALDH1A1 | |
| SCHEMBL13858911 | 0.83 | HTR2B (0.47) | MEN1KMT2ASLC6A2SLC6A4TACR1 | |
| SCHEMBL13859666 | 0.82 | POLB (0.43) | POLBMEN1KMT2AHRH3ALDH1A1 | |
| SCHEMBL13859074 | 0.80 | CARM1 (0.41) | KCNH2HRH3TACR1 | |
| SCHEMBL13859075 | 0.78 | CHRNA7 (0.42) | CCR2KCNH2HRH3ALDH1A1 | |
| SCHEMBL13859067 | 0.77 | KCNH2 (0.38) | POLBCCR2KCNH2SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528132-B2 | immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease; indazolyl [1,2,4]triazine compounds | SCHERING CORPORATION (US) | 2009-05-05 | — | — | US | disclosed |
| US-20080004257-A1 | Kinase inhibitors | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004257-A1 | Kinase inhibitors | MAP3K1, MAP3K13, MAP3K6 | POLB 1083/4885MEN1 1654/4885KMT2A 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.